Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3)
Phase I/II Clinical Trial
A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)